Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LASN01 in Thyroid Eye Disease
NCT06226545Phase 2Completed
- Sponsor
- Lassen Therapeutics
- Start
- Mar 2024
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of LASN01 in thyroid eye disease (TED) (4 arms), sponsored by Lassen Therapeutics. Primary endpoints: Percentage of Participants Showing a Response in Proptosis (≥2 mm Decrease) at 36 weeks and Number of Participants With Adverse Events at 56 weeks. Started Mar 2024; status: completed.
02
Drugs
LASN01
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06226545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06226545.